Charles Divita III Sells 27,731 Shares of Teladoc Health (NYSE:TDOC) Stock

Key Points

• Insider sale: CEO Charles Divita III sold 27,731 shares on March 11 at an average price of $5.49 for about $152,243, reducing his direct stake by 7.06% to 364,784 shares (valued ~ $2.00M).
• Mixed results but negative outlook: Teladoc slightly beat quarterly EPS and revenue (EPS $(0.14) vs. $(0.19) est.; revenue $642.3M) but remains unprofitable and issued negative Q1 and FY2026 EPS guidance.
• Market and analyst context: The stock trades near $5.38 with a market cap ~ $959M, and analysts have trimmed price targets (average target $7.76) leaving a consensus rating around "Hold."

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) CEO Charles Divita III sold 27,731 shares of the company's stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the sale, the chief executive officer directly owned 364,784 shares of the company's stock, valued at approximately $2,002,664.16. This represents a 7.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Teladoc Health Price Performance

NYSE:TDOC traded down $0.10 during midday trading on Thursday, hitting $5.38. 3,220,743 shares of the stock were exchanged, compared to its average volume of 6,903,328. The company has a market capitalization of $958.88 million, a price-to-earnings ratio of -4.71 and a beta of 2.13. The company has a current ratio of 2.77, a quick ratio of 2.67 and a debt-to-equity ratio of 0.72. Teladoc Health, Inc. has a one year low of $4.40 and a one year high of $9.77. The business has a 50-day moving average price of $5.69 and a two-hundred day moving average price of $7.08.

Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. The company had revenue of $642.27 million for the quarter, compared to analysts' expectations of $635.33 million. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The firm's revenue for the quarter was up .3% on a year-over-year basis. During the same period last year, the firm earned ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450--0.350 EPS and its FY 2026 guidance at -1.100--0.700 EPS. Sell-side analysts predict that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Oppenheimer reduced their target price on shares of Teladoc Health from $12.00 to $7.00 and set an "outperform" rating for the company in a report on Tuesday, March 3rd. BMO Capital Markets decreased their price target on Teladoc Health from $8.00 to $5.00 and set a "market perform" rating for the company in a research report on Thursday, February 26th. Barclays started coverage on Teladoc Health in a report on Tuesday, December 9th. They set an "equal weight" rating and a $8.50 price objective on the stock. Canaccord Genuity Group decreased their target price on shares of Teladoc Health from $12.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, February 26th. Finally, Stifel Nicolaus dropped their target price on shares of Teladoc Health from $8.00 to $6.00 and set a "hold" rating on the stock in a research report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Teladoc Health currently has an average rating of "Hold" and an average target price of $7.76.

Hedge Funds Weigh In On Teladoc Health

Several institutional investors and hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. lifted its position in shares of Teladoc Health by 177.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider's stock worth $31,000 after purchasing an additional 2,810 shares in the last quarter. IFP Advisors Inc grew its position in Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider's stock valued at $31,000 after purchasing an additional 3,210 shares in the last quarter. Aster Capital Management DIFC Ltd increased its stake in Teladoc Health by 101.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider's stock valued at $37,000 after buying an additional 2,425 shares during the period. International Assets Investment Management LLC acquired a new position in Teladoc Health in the 4th quarter valued at approximately $45,000. Finally, Bayforest Capital Ltd purchased a new stake in Teladoc Health in the 3rd quarter worth approximately $58,000. Hedge funds and other institutional investors own 76.82% of the company's stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc's service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.